← Back to patent-cliff list
马来酸依那普利
Tier C — Watch / tradeEnalapril Maleate
Bausch Health Companies Inc
Originator
1985
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ACE
Brand：Epaned、Ednit、Xanef、Crinoren、Enalaped、Innovace Melt (freeze-dried oral wafer)、Dabonal、Naprilene、Enapren、Ditensor、Renivace、Benalapril、Baripril、Innovace、Renitec
Indications (approved)：心脏衰竭、高血压、心肌梗塞、心绞痛、左心室功能不全
Regional status
US
批准上市
1985-12-24
EU
批准上市
2023-11-15
China
批准上市
2000-12-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Enalapril Maleate?
Approved indications include: 心脏衰竭, 高血压, 心肌梗塞, 心绞痛, 左心室功能不全.
When does the Enalapril Maleate patent expire?
No public expiry year is available for Enalapril Maleate yet; this page updates once verified.
How do I get a quote for Enalapril Maleate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25